Efficacy and safety of boosted darunavir-based antiretroviral therapy in HIV-1-positive patients: results from a meta-analysis of clinical trials-Reference-Cited by-同舟云学术

Efficacy and safety of boosted darunavir-based antiretroviral therapy in HIV-1-positive patients: results from a meta-analysis of clinical trials

Published:2018-03-27 Issue:1 Volume:8 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Antinori A.,Lazzarin A.,Uglietti A.,Palma M.,Mancusi D.,Termini R.

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-018-23375-6.pdf

Reference58 articles.

1. Prezista 800®. Summary of Product Characteristics (SmPC). Available from: http://www.ema.europa.eu/docs/it_IT/document_library/EPAR__Product_Information/human/000707/WC500041756.pdf , Accessed March 21, 2017.

2. Prezista 600®. Summary of Product Characteristics (SmPC). Available from: http://www.ema.europa.eu/docs/it_IT/document_library/EPAR__Product_Information/human/000707/WC500041756.pdf , Accessed March 21, 2017.

3. Deeks, E. D. Darunavir: a review of its use in the management of HIV-1 infection. Drugs 74, 99–125 (2014).

4. Ortiz, R. et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS. 22, 1389–1397 (2008).

5. Mills, A. M. et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS. 23, 1679–1688 (2009).

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HIV epidemiology, prevention, treatment, and implementation strategies for public health;The Lancet;2024-02

2. Cardiovascular risks associated with protease inhibitors for the treatment of HIV;Expert Opinion on Drug Safety;2021-07-26

3. Cost-effectiveness and budget impact of dolutegravir/lamivudine for treatment of human immunodeficiency virus (HIV-1) infection in the United States;Journal of Managed Care & Specialty Pharmacy;2021-07

4. A Low Level of Darunavir Resistance–Associated Mutation Emergence in Patients With Virological Failure During Long-term Use of Darunavir in People With HIV. The ANRS CO3 Aquitaine Cohort;Open Forum Infectious Diseases;2020-11-19

5. High levels of HIV drug resistance among adults failing second-line antiretroviral therapy in Namibia;Medicine;2020-09-11